Bio-Path Holdings Advances Clinical Pipeline for 2025
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Targeted Oncology19h
MRD Monitoring Post-Transplant Predicts Survival in TP53-Mutant MDS/AML
David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...
manilatimes23h
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody ® First-in-human study enrolling adult patients with ...
Bio-Path Holdings, Inc.: Bio-Path Holdings Provides 2025 Clinical and Operational Update
Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Hold ...